1. Volume 66, Issue 3, Pages 666-668 (March 2017)
Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase- independent target of sorafenib in hepatocellular carcinoma” 
Wei-Tien Tai, Ann-Lii Cheng, Chung-Wai Shiau, Hsiang-Po Huang, Jui-Wen Huang, Pei-Jer Chen, Kuen-Feng Chen 
Journal of Hepatology 
Volume 66, Issue 3, Pages (March 2017)
DOI: /j.jhep
Copyright © Terms and Conditions

2. Fig. 3
Inhibition of SHP-1 reverses effects of sorafenib and SC-1 on phospho-STAT3 and apoptosis. (A) Left panel, vanadate, a non-specific phosphatase inhibitor. Right panel, specific SHP-1 inhibitor. Columns, mean; bars, SD (n=3) ∗p<0.05. (B) Left panel, silencing SHP-1 by siRNA reduces effects of sorafenib or SC-1 on p-STAT3 in HCC cells. PLC5 cells were transfected with control siRNA or SHP-1 siRNA for 24h then treated with sorafenib or SC-1 for another 24h. Middle panel, the activity of SHP-1 in PLC5 cells. Columns, mean; bars, SD (n=3) ∗p<0.05. Right panel, effects of sorafenib or SC-1 on protein interactions between SHP-1 and STAT3. PLC5 cells were treated with sorafenib or SC-1 at 10μM for 24h. (C) Knock-down of SHP-2 does not affect the effects of sorafenib or SC-1 on p-STAT3 and apoptosis. Knock-down of PTP-1B does not affect the effects of sorafenib on p-STAT3 and apoptosis. PLC5 cells were transfected with control siRNA or SHP-2 siRNA or PTP-1B siRNA for 24h then treated with sorafenib or SC-1 at 10μM for 24h.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © Terms and Conditions

3. Fig. 4
SC-1 down-regulates p-STAT3 and induces apoptosis in HUVEC cells. (A) Effects of sorafenib or SC-1 on p-STAT3 (left panel) and apoptosis (right panel) in HUVEC cells. Cells were exposed to sorafenib or SC-1 at 10μM for 24h. Apoptotic cells were assayed by flow cytometry (sub-G1). (B) Effects of SC-1 on TRAIL sensitization in HCC. PLC5 cells were treated with SC-1 (10μM) and/or TRAIL (100ng/ml) for 24h. (C) Silencing Raf-1 does not affect the effects of the drugs on p-STAT3. PLC5 cells were transfected with control siRNA or Raf-1 siRNA for 24h then treated with sorafenib or SC-1 at 10μM for 24h. (D) Effect of sorafenib and SC-1 on JAK2 activity. PLC5 cells were exposed to sorafenib or SC-1 at 10μM for 24h. Points, mean; bars, SD (n=6). (E) Effects of 5μM and 10μM sorafenib treatments on SOCS-1 and SOCS-3. Sk-Hep1 cells were pre-treated with IL-6 for 24h then were treated with sorafenib or SC-1 at the indicated doses for another 24h in the presence of IL-6. (F) Effects of STAT-C on apoptosis induced by SC-1 in PLC5 cells. Cells (wild type or ectopic expression of STAT3-C) were exposed to sorafenib or SC-1 at 10μM for 24h. (G) Effects of sorafenib and SC-1 on SHP-1. Columns, mean; bars, SD (n=3) ∗p<0.05.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © Terms and Conditions